Mitochondrial dynamics refers to the continuous processes of fusion and fission that maintain mitochondrial morphology, distribution, and quality control within cells. These opposing processes are essential for mitochondrial health, ATP production, calcium homeostasis, and apoptotic regulation[1]. In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), dysregulation of mitochondrial dynamics represents a central pathogenic mechanism contributing to neuronal dysfunction and death[2].
The balance between fusion and fission determines mitochondrial morphology—from elongated, interconnected networks to fragmented discrete organelles. This dynamics continuum is governed by a family of dynamin-related proteins (DRPs) that mediate membrane remodeling events on mitochondrial membranes[3]. Understanding how these processes go awry in neurodegeneration provides critical insights into disease mechanisms and therapeutic targeting.
Mitochondrial fusion is mediated by three large GTPases located on the outer and inner mitochondrial membranes. These dynamin-related proteins orchestrate the sequential fusion of both membranes to form a continuous mitochondrial network[4].
Mitofusins (MFN1 and MFN2)
Mitofusin-1 (MFN1) and Mitofusin-2 (MFN2) are dynamin-related GTPases located on the outer mitochondrial membrane. They mediate outer membrane fusion through their GTPase activity and form homotypic and heterotypic complexes:
Both proteins contain an N-terminal GTPase domain, middle domain for dimerization, C-terminal transmembrane regions, and HR1 and HR2 heptad repeat domains.
OPA1 (Optic Atrophy 1)
OPA1 is a dynamin-related GTPase located on the inner mitochondrial membrane that mediates inner membrane fusion. It is essential for cristae maintenance, mtDNA stability, and apoptotic resistance[7]:
Mitochondrial fission is mediated by DRP1 (Dynamin-related protein 1), which is recruited from the cytosol to mitochondria by outer membrane receptors[8].
DRP1 (Dynamin-related protein 1)
DRP1 is a cytosolic GTPase that assembles into ring-like structures around mitochondria to mediate fission:
Fission Receptors
| Receptor | Function | Tissue Expression |
|---|---|---|
| FIS1 | Adapter protein, recruits DRP1 | Ubiquitous |
| MFF | Major DRP1 receptor | High in brain |
| MiD49/50 | DRP1 recruitment | Neuron-enriched |
The complete mitochondrial dynamics cycle involves:
Mitochondrial dynamics proteins are extensively regulated by post-translational modifications that respond to cellular signaling and stress conditions[9]:
| Modification | Enzyme | Target | Effect |
|---|---|---|---|
| Phosphorylation (Ser616) | PKA | DRP1 | Inhibits fission |
| Phosphorylation (Ser637) | PKA | DRP1 | Inhibits fission |
| Phosphorylation (Ser600) | CDK1 | DRP1 | Promotes fission |
| Phosphorylation (Ser27) | PKA | MFN1/2 | Inhibits fusion |
| Dephosphorylation | PP1 | MFN1/2 | Restores fusion |
| Ubiquitination | Parkin | MFN1/2 | Targets for degradation |
| Sumoylation | SENP5 | OPA1 | Stabilizes fusion proteins |
| O-GlcNAcylation | OGT | MFN2 | Protects against stress |
Calcium flux regulates dynamics through:
ATP and AMP levels influence fusion-fission balance:
Alzheimer's disease features prominent mitochondrial dysfunction, with impaired fusion representing an early event in disease pathogenesis[12]. Multiple mechanisms contribute to dynamics deficits in AD.
Amyloid-beta (Aβ) directly interacts with mitochondrial proteins:
Tau pathology disrupts mitochondrial dynamics:
Studies in AD models demonstrate:
Strategies targeting dynamics in AD include:
Parkinson's disease involves prominent mitochondrial dysfunction, particularly in dopaminergic neurons of the substantia nigra pars compacta[17]. The PINK1/Parkin pathway regulates mitochondrial quality control, but fusion and fission also play critical roles.
The PINK1/Parkin pathway regulates dynamics:
α-Synuclein aggregation impacts dynamics:
LRRK2 (leucine-rich repeat kinase 2) mutations linked to PD:
ALS features mitochondrial dysfunction in motor neurons, with dynamics defects contributing to disease pathogenesis[22]. Multiple ALS-causing genes affect mitochondrial dynamics.
Superoxide dismutase 1 (SOD1) mutations:
C9orf72 repeat expansions:
TDP-43 aggregates in ALS:
FUS (fused in sarcoma) mutations:
Huntington's disease involves prominent mitochondrial deficits, with mutant huntingtin directly affecting dynamics machinery[27].
Mutant huntingtin (mHtt) impacts dynamics:
Dynamics defects contribute to:
FTD shares mechanistic overlaps with ALS:
MSA features:
PSP involves:
Live-cell microscopy
Super-resolution microscopy
Mitochondrial matrix-targeted reporters
| Marker | Measurement | Significance |
|---|---|---|
| OPA1 processing | Western blot | Long vs short isoforms |
| MFN1/2 levels | Immunoblot | Protein expression |
| DRP1 recruitment | Cell fractionation | Fission activity |
| Phosphorylation status | Phospho-specific antibodies | Activity state |
| GTPase activity | GTP hydrolysis assay | Functional status |
| Compound | Target | Mechanism | Stage |
|---|---|---|---|
| Mdivi-1 | DRP1 | Inhibit fission | Phase I/II |
| Mitochondrial fusion enhancers | MFN1/2 | Promote GTPase activity | Preclinical |
| OPA1 stabilizers | OPA1 | Prevent proteolysis | Research |
| P110 | DRP1 | Selective inhibition | Preclinical |
Optimal therapeutic approaches may combine:
Chan et al. Mitochondrial fusion and fission in neuronal function. Neuroscience. 2020. ↩︎
Chen et al. Mitochondrial dynamics in neurodegeneration. Trends in Cell Biology. 2023. ↩︎
Giacomello et al. Mitochondrial fission and fusion in cellular stress. Nature Reviews Molecular Cell Biology. 2023. ↩︎
Liu et al. Mitofusin 2 in Alzheimer's disease. Molecular Neurobiology. 2022. ↩︎
Chen et al. Mitofusin-mediated mitochondrial fusion. PNAS. 2007. ↩︎
Zuchner et al. Mutations in the mitochondrial GTPase mitofusin 2. NEJM. 2004. ↩︎
Liao et al. OPA1 mutations and optic atrophy. Brain. 2021. ↩︎
Song et al. Drp1 and mitochondrial fission. Trends in Cell Biology. 2022. ↩︎
Peng et al. Regulation of mitochondrial dynamics in neurodegeneration. Acta Neuropathologica. 2023. ↩︎
高铁梅 et al. Calcium regulation of mitochondrial fusion. Cell. 2019. ↩︎
Wang et al. AMPK regulates mitochondrial dynamics. Nature Communications. 2019. ↩︎
Wang et al. Mitochondrial dysfunction in Alzheimer's disease. Neurobiology of Disease. 2022. ↩︎
Manczak et al. Mitochondria-targeted amyloid beta. Human Molecular Genetics. 2016. ↩︎
Kopeidou et al. Tau pathology and mitochondrial dysfunction. Acta Neuropathologica. 2022. ↩︎
Wang et al. Mitofusin1 and mitofusin2 in AD. Neurobiology of Disease. 2019. ↩︎
Yang et al. Mitochondrial dynamics modulation as therapy. Nature Reviews Neurology. 2023. ↩︎
Park et al. Mitochondrial dynamics in Parkinson's disease. Neurobiology of Disease. 2023. ↩︎
Narendra et al. Parkin induces mitochondrial autophagy. J Cell Biol. 2008. ↩︎
Poehler et al. Alpha-synuclein and mitochondrial dynamics. Ann Neurol. 2014. ↩︎
Rideout et al. LRRK2 and mitochondrial dysfunction. Brain. 2016. ↩︎
Xie et al. Mitofusin2 in Parkinson's disease models. Scientific Reports. 2019. ↩︎
Shi et al. Mitochondrial dysfunction in ALS. Neurobiology of Aging. 2020. ↩︎
Liu et al. SOD1 mutations and mitochondrial dynamics. J Mol Biol. 2020. ↩︎
Lopez-Gonzalez et al. C9orf72 and mitochondrial dysfunction. Brain. 2019. ↩︎
Wang et al. TDP-43 and mitochondrial dynamics. Nature Neuroscience. 2018. ↩︎
Deng et al. FUS and mitochondrial dysfunction in ALS. Brain. 2015. ↩︎
Costa et al. Mutant huntingtin and mitochondrial dynamics. Brain. 2020. ↩︎
Shirendeb et al. Mutant huntingtin interactions with mitochondrial proteins. JBC. 2009. ↩︎
Quintanilla et al. Mitochondrial bioenergetic deficits in HD. Brain. 2013. ↩︎
Rascovsky et al. TDP-43 pathology in FTD. Brain. 2019. ↩︎
Stefanova et al. Mitochondrial dysfunction in MSA. Mov Disord. 2019. ↩︎
Zhang et al. Gene therapy for mitochondrial dynamics. Nature Biotechnology. 2023. ↩︎ ↩︎